文献速递眼底病与葡萄膜炎

全氟丙烷气动玻璃体溶解术治疗玻璃体黄斑牵引伴或不伴黄斑裂孔:DRCR视网膜网络AG与AH方案

Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH.
PubMed 文献 · Ophthalmology · 2021-05-12

两项多中心研究评估气动玻璃体溶解术(PVL)治疗玻璃体黄斑牵引(VMT)伴或不伴全层黄斑裂孔(FTMH)。AG方案随机对照比较PVL与假注射,AH方案单臂评估PVL对FTMH的疗效。因视网膜脱离和裂孔发生率高于预期,两项研究均提前终止。

要点

  • PVL组78%实现中心VMT解除,显著高于假注射组的9%(调整风险差66%,P<0.001)。
  • PVL治疗FTMH的8周闭合率为29%(95%CI 16%-45%)。
  • 59只接受PVL的眼中有7只(12%)发生孔源性视网膜脱离或视网膜裂孔,导致研究提前终止。

核心结论

  • 在多数VMT眼中,PVL可诱导玻璃体后脱离。
  • 在FTMH眼中,PVL使约三分之一的眼实现裂孔闭合。
  • 因视网膜脱离和视网膜裂孔的安全性担忧,两项研究均提前终止。

研究设计与样本

  • AG方案为随机临床试验,比较PVL与观察(假注射)治疗不伴FTMH的VMT,纳入46名成人。
  • AH方案为单臂研究,评估PVL治疗FTMH,纳入35只眼。
  • 两项研究共涉及28个中心,参与者为中央VMT(玻璃体黄斑粘连≤3000 μm)的成人。
  • AG方案中视力为20/32至20/400;AH方案中FTMH最窄处≤250 μm,视力为20/25至20/400。
  • PVL使用全氟丙烷(C3F8)气体。

主要发现

  • AG方案24周时,PVL组23只眼中18只(78%)实现中心VMT解除且无需补救性玻璃体切除术,假注射组22只眼中2只(9%)实现。
  • AG方案24周视力平均变化:PVL组+6.7个字母,假注射组+6.1个字母(调整差-0.8,95%CI -6.1至4.5;P=0.77)。
  • AH方案8周时,35只眼中10只(29%,95%CI 16%-45%)实现FTMH闭合且无需补救性玻璃体切除术。
  • AH方案8周视力平均变化为-1.5个字母(95%CI -10.3至7.3个字母)。
  • 合并研究,接受PVL的59只眼中7只(12%,95%CI 6%-23%)发生孔源性视网膜脱离(6只)或视网膜裂孔(1只)。

关键数值与推荐

  • AG方案主要结局为中心VMT解除(24周),PVL组78% vs 假注射组9%,调整风险差66%(95%CI 44%-88%),P<0.001。
  • AH方案主要结局为FTMH闭合(8周),闭合率29%(95%CI 16%-45%)。
  • 安全性:PVL后孔源性视网膜脱离或视网膜裂孔发生率为12%(95%CI 6%-23%)。

临床怎么用

  • PVL可有效解除VMT,但需权衡视网膜脱离和视网膜裂孔的风险。
  • 对于FTMH,PVL的闭合率约三分之一,可作为不愿或不宜手术者的可选方案之一。
  • 治疗前应充分告知患者PVL相关视网膜脱离和裂孔的风险。

局限性

  • 两项研究均因安全性问题提前终止,样本量有限(AG方案46人,AH方案35只眼)。
  • AH方案为单臂研究,缺乏对照组。
  • 随访时间较短(AG方案24周,AH方案8周)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate pneumatic vitreolysis (PVL) in eyes with vitreomacular traction (VMT) with and without full-thickness macular hole (FTMH). DESIGN: Two multicenter (28 sites) studies: a randomized clinical trial comparing PVL with observation (sham injection) for VMT without FTMH (Protocol AG) and a single-arm study assessing PVL for FTMH (Protocol AH). PARTICIPANTS: Participants were adults with central VMT (vitreomacular adhesion was ≤3000 μm). In Protocol AG, visual acuity (VA) was 20/32 to 20/400. In Protocol AH, eyes had a FTMH (≤250 μm at the narrowest point) and VA of 20/25 to 20/400. METHODS: Pneumatic vitreolysis using perfluoropropane (C3F8) gas. MAIN OUTCOME MEASURES: Central VMT release at 24 weeks (Protocol AG) and FTMH closure at 8 weeks (Protocol AH). RESULTS: From October 2018 through February 2020, 46 participants were enrolled in Protocol AG, and 35 were enrolled in Protocol AH. Higher than expected rates of retinal detachment and tear resulted in early termination of both protocols. Combining studies, 7 of 59 eyes (12% [95% CI, 6%-23%]; 2 eyes in Protocol AG, 5 eyes in Protocol AH) that received PVL developed rhegmatogenous retinal detachment (n = 6) or retinal tear (n = 1). At 24 weeks in Protocol AG, 18 of 23 eyes in the PVL group (78%) versus 2 of 22 eyes in the sham group (9%) achieved central VMT release without rescue vitrectomy (adjusted risk difference, 66% [95% CI, 44%-88%]; P< 0.001). The mean change in VA from baseline at 24 weeks was 6.7 letters in the PVL group and 6.1 letters in the sham group (adjusted difference, -0.8 [95% CI, -6.1 to 4.5]; P = 0.77). In Protocol AH, 10 of 35 eyes (29% [95% CI, 16%-45%]) achieved FTMH closure without rescue vitrectomy at 8 weeks. The mean change in VA from baseline at 8 weeks was -1.5 letters (95% CI, -10.3 to 7.3 letters). CONCLUSIONS: In most eyes with VMT, PVL induced hyaloid release. In eyes with FTMH, PVL resulted in hole closure in approximately one third of eyes. These studies were terminated early because of safety concerns related to retinal detachments and retinal tears.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Chan CK, Mein CE, Glassman AR, et al. Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH. Ophthalmology. 2021. PMID: 33989683. doi:10.1016/j.ophtha.2021.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。